PDE 5 inhibition with udenafil improves left ventricular systolic/diastolic functions and exercise capacity in patients with chronic heart failure with reduced ejection fraction; A 12-week, randomized, double-blind, placebo-controlled trial

2015 ◽  
Vol 169 (6) ◽  
pp. 813-822.e3 ◽  
Author(s):  
Kyung-Hee Kim ◽  
Hyung-Kwan Kim ◽  
In-Chang Hwang ◽  
Hyun-Jai Cho ◽  
Nari Je ◽  
...  
Keyword(s):  
Heart Failure ◽  
Chronic Heart Failure ◽  
Ejection Fraction ◽  
Exercise Capacity ◽  
Controlled Trial ◽  
Left Ventricular ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Reduced Ejection Fraction ◽  
Diastolic Functions

Comparison of the prognosis and outcome of heart failure with reduced ejection fraction patients treated with sacubitril/valsartan according to age

2021 ◽  
Author(s):  
Mohammad Abumayyaleh ◽  
Ibrahim El-Battrawy ◽  
Marvin Kummer ◽  
Christina Pilsinger ◽  
Katherine Sattler ◽  
...  
Keyword(s):  
Heart Failure ◽  
Chronic Heart Failure ◽  
Ejection Fraction ◽  
Older Patients ◽  
Left Ventricular ◽  
Adult Patients ◽  
Left Ventricular Ejection ◽  
Ventricular Ejection Fraction ◽  
Reduced Ejection Fraction ◽  
The Impact

The treatment with sacubitril/valsartan in patients suffering from chronic heart failure with reduced ejection fraction increases left ventricular ejection fraction and decreases the risk of sudden cardiac death. We conducted a retrospective analysis regarding the impact of age differences on the treatment outcome of sacubitril/valsartan in patients with chronic heart failure with reduced ejection fraction. Patients were defined as adults if ≤65 years (n = 51) and older if >65 years of age (n = 76). The incidence of ventricular arrhythmias at 1-year follow-up was comparable in both groups (30.8 vs 26.5%; p = 0.71). The mortality rate in adult patients is significantly lower as compared with older patients (2 vs 14.5%; log-rank = 0.04). Older patients may suffer remarkably more side effects than adult patients (21.1 vs 11.8%; p = 0.03).

scholarly journals A randomised, double‐blind, placebo‐controlled trial of metformin on myocardial efficiency in insulin‐resistant chronic heart failure patients without diabetes

2019 ◽  
Vol 22 (9) ◽  
pp. 1628-1637 ◽  
Author(s):  
Anders Hostrup Larsen ◽  
Niels Jessen ◽  
Helene Nørrelund ◽  
Lars Poulsen Tolbod ◽  
Hendrik Johannes Harms ◽  
...  
Keyword(s):  
Heart Failure ◽  
Chronic Heart Failure ◽  
Controlled Trial ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Heart Failure Patients ◽  
Insulin Resistant ◽  
Myocardial Efficiency

scholarly journals Sodium restriction in patients with chronic heart failure and reduced ejection fraction: A randomized controlled trial

2021 ◽  
Author(s):  
Juan Betuel Ivey-Miranda ◽  
Eduardo Almeida-Gutierrez ◽  
Raul Herrera-Saucedo ◽  
Edith Liliana Posada-Martinez ◽  
Adolfo Chavez-Mendoza ◽  
...  
Keyword(s):  
Heart Failure ◽  
Randomized Controlled Trial ◽  
Chronic Heart Failure ◽  
Ejection Fraction ◽  
Controlled Trial ◽  
Sodium Restriction ◽  
Reduced Ejection Fraction ◽  
Randomized Controlled
Sign in / Sign up

Export Citation Format

Share Document